Visual Abstract

Background: The efficacy and safety of switching to Gla-300 in T2DM uncontrolled on BI has been demonstrated in RCTs and RWE studies in the US and EU. However, similar data in wider geographic regions are limited. ARTEMIS-DM is a multicentre, interventional, single-arm, Phase IV study aimed to evaluate the impact of this switch in 14 countries across Asia, Middle East - Africa and Latin America.

Methods: ARTEMIS-DM study enrolled participants with HbA1c between 7.5 and 10%. Primary endpoint was change in HbA1c from baseline to 26 weeks.

Results: Of 372 participants (50% male), the mean (SD) age was 60.9 (10.0) years and BMI was 29.57 (5.43) kg/m2. Majority of participants (62.6%) were <65 years and median diabetes duration was 12 years. A total of 222 (59.7%) participants had insulin glargine (100 U/mL) as previous BI. There was a decrease in mean HbA1c and fasting plasma glucose (FPG) at Weeks 12 and 26 (Table). Any hypoglycemic event occurred in 20.4% of the people with 1 (0.3%) event of severe hypoglycemia and 9.4% of people experienced nocturnal hypoglycemia. With a recommended titration algorithm, the mean dose increased from 0.35 U/kg at baseline to 0.5 U/kg at Week 26.

Conclusion: In people with T2DM uncontrolled on previous BI, switching to Gla-300 with optimal titration was associated with improved glycemic control and low incidence of hypoglycemia.

graphic
View largeDownload slide
Disclosure

B. Sethi: None. K. Alrubeaan: None. M. Unubol: None. M. N. Mabunay: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. M. Naqvi: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. B. Berthou: None. V. Pilorget: Employee; Self; Sanofi. G. Frechtel: None.

Funding

Sanofi

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.